Abivax shares rose sharply after updated data provided reassurances for investors following earlier safety-related volatility tied to obefazimod in ulcerative colitis. The stock movement tracked new information from the ABTECT Maintenance Part 2 supplemental portion of the Phase 3 program. Coverage described clinical remission rates among induction nonresponders and highlighted endoscopic outcomes at Week 44 for continued 50 mg dosing. It also pointed to a reported absence of new safety signals since the earlier disclosure of malignancies among trial participants. For biotech investors, the update matters because maintenance efficacy data and the clarification of malignancy incidence relative to background ranges can influence perceptions of risk-benefit and regulatory readiness.